The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Interested in all sessions Cellular Therapy/Biotherapies? Then this is the package for you. We have also thrown in a couple of additional sessions you might also find interesting…
By far the best value to watch all the on-demand educational sessions from the 2024 AABB Annual Meeting and earn continuing education credit…
CABP CE Eligible
This session focuses on new FDA-approved gene therapies for sickle cell disease (SCD) and the critical aspects of coordinating care for gene therapy, including an approach to transfusion support and maximizing stem cell collections. With recent advancements in gene therapy offering a cure for SCD, effective coordination among multidisciplinary healthcare teams is essential to ensure optimal patient outcomes. Barriers to offering gene therapy for SCD may include alloimmunization to multiple antigens and an inability to collect sufficient autologous hematopoietic stem cells. The session will delve into the details of patient selection, pre-treatment assessments, treatment protocols, and coordination of complex care. Participants will have the opportunity to engage in discussions, case presentations, and a Q&A session with experts in the field of sickle cell disease, gene therapy and transfusion support. The session aims to share best practices and practical strategies for integrating gene therapy into the care plan for patients with SCD at both adult and pediatric institutions.
Learning Objectives
Review current FDA approved gene therapies and criteria for identifying suitable candidates
Discuss an approach to multidisciplinary care coordination with hematologists, transfusion and transplant specialists, and psychologists
Discuss an approach to safe transfusion support, particularly for those that may be difficult to match
Review and familiarize practitioners with stem cell mobilization and technical aspects of collections to enhance stem cell yield for patients with SCD
All relevant financial relationships have been mitigated.
By completing the evaluation, you are attesting to watching the presentation in its entirety. A certificate will be immediately provided after submission.
Credits Available
Purchasing this session will automatically provide ownership of all the individually purchasable attached CE products, regardless of their stated individual purchase restrictions.
AM24-SN-06-O: Operationalizing Delivery of Gene Therapy for Sickle Cell Disease (Enduring) Evaluation
This session will highlight advances in three areas of platelet research; stabilization methods through lyophilization, iPSC ex-vivo production, and synthetic nanoparticle technology are converging and can lead to long-lived platelet-based therapies targeted to address specific related pathologies…
This informative session will give an overview of inspections conducted by FDA’s Office of Inspections and Investigations (OII), Office of Biologics Inspectorate (OBI), including OBI’s role in regulatory inspections and current regulatory oversight…
Hematopoietic stem cells (HSCs) are the apex hematopoietic cell with the potential to produce robust and lifelong production of all blood cells. Thus, understanding the details of HSC molecular biology is critical to our understanding of human health and longevity…
Despite the need for diverse donors of blood, stem cells, and organs/tissues, such donors remain dramatically underrepresented in donor pools, across donation products.. This session will begin with a brief didactic component, where expert presenters (Dr…